Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Subscribe To Our Newsletter & Stay Updated
